Features of toll-like receptor type 9 expression on immunocompetent peripheral blood cells of patients with measles infection of varying severity

Abstract

Object of research: the level of the Toll-like receptor type 9 expression on peripheral blood lymphocytes and monocytes in patients with measles of varying severity, both with and without complications.
 The solved problem: identification of the relationship between changes in the level of production of the main cytokines and virus-specific immunoglobulins and the level of expression of the Toll-like receptor type 9 on immunocompetent peripheral blood cells of patients with measles infection of varying severity.
 The main scientific results: In patients with measles infection have been identified three types of cytokine response, each of which is characterized by different levels of changes in the expression of the main cytokines, immunoglobulins, and their avidity. It was shown that the levels of expression of major cytokines and virus-specific antibodies, as well as their avidity, are associated with the level of expression of the Toll-like receptor type 9. It has been demonstrated that moderate disease is associated with a significant increase in the level of expression of the Toll-like receptor type 9 on the immunocompetent peripheral blood cells, while their low expression leads to the development of severe forms of the disease. It has been shown that in moderate disease the risk of complications is associated with a lower level of expression of the Toll-like receptor compared to the group without complications. In groups of patients with a severe course of the disease a significant decrease in the level of expression of the Toll-like receptor type 9 was shown to be associated with the risk of complications.
 The field of practical use of the research results: medical institutions specializing in the treatment of socially significant infectious diseases.
 Innovative technological product: a method of advanced study of patients with and without measles infection of varying severity which allows to identify risk groups for the development of severe forms of the disease and complications, which in turn will allow the timely apply methods of immunomodulatory therapy and optimize the costs of the health system.
 Scope of application of an innovative technological product: inpatient and outpatient treatment and diagnostics of patients with socially significant infectious diseases.